Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by MWA Asset Management

MWA Asset Management grew its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 23.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,186 shares of the pharmaceutical company’s stock after acquiring an additional 603 shares during the quarter. MWA Asset Management’s holdings in Vertex Pharmaceuticals were worth $1,283,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of VRTX. Northwest Investment Counselors LLC acquired a new stake in Vertex Pharmaceuticals during the third quarter worth about $25,000. Dunhill Financial LLC increased its holdings in shares of Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 24 shares during the last quarter. Highline Wealth Partners LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter valued at approximately $27,000. Legacy Investment Solutions LLC acquired a new position in Vertex Pharmaceuticals in the third quarter valued at approximately $33,000. Finally, Brown Lisle Cummings Inc. purchased a new position in Vertex Pharmaceuticals in the fourth quarter worth approximately $30,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Down 2.5 %

Shares of NASDAQ VRTX opened at $469.32 on Friday. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. The business has a 50-day moving average of $435.84 and a two-hundred day moving average of $462.87.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Bank of America reduced their target price on Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating on the stock in a research report on Thursday, December 19th. William Blair reaffirmed an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. Scotiabank lifted their price target on shares of Vertex Pharmaceuticals from $430.00 to $433.00 and gave the company a “sector perform” rating in a research report on Friday, January 31st. Cantor Fitzgerald restated an “overweight” rating and issued a $480.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, January 31st. Finally, Citigroup started coverage on shares of Vertex Pharmaceuticals in a report on Thursday, November 14th. They issued a “buy” rating and a $575.00 target price for the company. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $502.58.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.